Immunome, Inc. (NASDAQ:IMNM) Receives $29.80 Consensus PT from Brokerages

Immunome, Inc. (NASDAQ:IMNM) has earned a consensus rating of “Buy” from the six ratings firms that are currently covering the stock, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have covered the stock in the last year is $29.80.

Several research analysts have recently issued reports on the company. Piper Sandler began coverage on Immunome in a research note on Friday, May 31st. They set an “overweight” rating and a $27.00 price target for the company. Wedbush reissued an “outperform” rating and issued a $33.00 target price on shares of Immunome in a research note on Thursday, July 25th. JPMorgan Chase & Co. began coverage on shares of Immunome in a research note on Tuesday, April 30th. They issued an “overweight” rating and a $24.00 target price for the company. Finally, Guggenheim initiated coverage on shares of Immunome in a research note on Monday, April 15th. They issued a “buy” rating and a $35.00 target price for the company.

Insider Transactions at Immunome

In other news, Director Jean Jacques Bienaime bought 2,000 shares of the firm’s stock in a transaction dated Tuesday, May 21st. The stock was acquired at an average price of $13.57 per share, for a total transaction of $27,140.00. Following the acquisition, the director now owns 9,615 shares of the company’s stock, valued at $130,475.55. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 8.60% of the company’s stock.

Hedge Funds Weigh In On Immunome

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Immunome in the second quarter valued at approximately $97,000. EntryPoint Capital LLC grew its position in Immunome by 21,864.0% in the first quarter. EntryPoint Capital LLC now owns 5,491 shares of the company’s stock valued at $136,000 after acquiring an additional 5,466 shares in the last quarter. Jump Financial LLC acquired a new stake in Immunome in the fourth quarter valued at approximately $172,000. Sequoia Financial Advisors LLC acquired a new stake in Immunome in the second quarter valued at approximately $206,000. Finally, Clear Creek Financial Management LLC grew its position in Immunome by 18.2% in the second quarter. Clear Creek Financial Management LLC now owns 26,188 shares of the company’s stock valued at $317,000 after acquiring an additional 4,035 shares in the last quarter. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Immunome Stock Performance

Shares of NASDAQ IMNM opened at $15.45 on Wednesday. The firm has a market capitalization of $926.52 million, a P/E ratio of -2.05 and a beta of 1.79. Immunome has a one year low of $6.13 and a one year high of $30.96. The company’s fifty day moving average is $13.89 and its two-hundred day moving average is $17.67.

Immunome (NASDAQ:IMNM) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.46. The business had revenue of $1.03 million during the quarter, compared to the consensus estimate of $4.00 million. Immunome had a negative return on equity of 37.33% and a negative net margin of 1,829.44%. On average, sell-side analysts forecast that Immunome will post -1.45 earnings per share for the current fiscal year.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.